
ANIX Stock Forecast & Price Target
ANIX Analyst Ratings
Bulls say
Anixa Biosciences is expected to showcase encouraging Phase 1 data from its breast cancer vaccine, which has shown positive immune responses in 74% of participants and generated top line revenues of $506,661 and $1,176,939 in 2020 and 2019 respectively. Additionally, its CAR-T program for ovarian cancer has also shown promising results, with top line revenues of $1,233,704 and $2,004,835 in 2020 and 2019 respectively, indicating potential for further growth and success in the future.
Bears say
Anixa Biosciences is an early-stage biotechnology company with promising but early data for its cancer prevention vaccine, and potential for durable treatment of ovarian cancer with its CAR-T therapy program. While the company's approaches are differentiated, the early stage of development and limited financial resources may present a high-risk investment opportunity.
This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
ANIX Analyst Forecast & Price Prediction
Start investing in ANIX
Order type
Buy in
Order amount
Est. shares
0 shares